FDA Removes 12 Peptides From Category 2 List: What the April 2026 Order Means for Research Sourcing
On April 15, 2026, the FDA published a Federal Register notice removing twelve peptides from its Category 2 restricted-compounding list, with the change taking effect April 23, 2026. The list was originally created in late 2023 after safety concerns were raised about compounding these substances. According to public reporting, the companies that had nominated the peptides for restriction have since withdrawn those nominations, which prompted the delisting.
The twelve affected peptides include several compounds widely referenced in laboratory research: BPC-157, TB-500, GHK-Cu, MOTS-c, Epitalon, Semax, KPV, DSIP, LL-37, DiHexa, PEG-MGF, and Melanotan II. Coming off the Category 2 list does not make these peptides FDA-approved drugs, and it is a separate regulatory step from the Pharmacy Compounding Advisory Committee's review of seven peptides for the 503A Bulks List, a topic our team has covered separately as that meeting approaches.
For the research community, the practical takeaway is narrower than the headlines suggest. Removal from a restricted list changes what licensed compounding pharmacies may prepare under physician oversight. It says nothing about the purity, identity, or quality of material sourced through any particular channel. Reproducible research has always depended on knowing exactly what is in the vial, not on a compound's compounding status in Washington. That is why every peptide Kynetide ships continues to carry third-party HPLC verification to 99%+ purity and a batch-specific Certificate of Analysis, regardless of how any single compound's regulatory category shifts.
Kynetide's products are supplied strictly for in-vitro and laboratory research use. They are not drugs, cosmetics, or supplements, and are not intended for human or veterinary use. Researchers should always consult current FDA guidance and their institution's compliance requirements when sourcing and handling any peptide.
